| Literature DB >> 17280753 |
Masaji Okada1, Yoko Kita, Toshihiro Nakajima, Noriko Kanamaru, Satomi Hashimoto, Tetsuji Nagasawa, Yasufumi Kaneda, Shigeto Yoshida, Yasuko Nishida, Reiko Fukamizu, Yoshie Tsunai, Ruriko Inoue, Hitoshi Nakatani, Yumi Namie, Junko Yamada, Kyoko Takao, Ritsuko Asai, Ryoko Asaki, Makoto Matsumoto, David N McMurray, E C Dela Cruz, E V Tan, R M Abalos, J A Burgos, Robert Gelber, Mitsunori Sakatani.
Abstract
We have developed a novel tuberculosis (TB) vaccine; a combination of the DNA vaccines expressing mycobacterial heat shock protein 65 (HSP65) and interleukin 12 (IL-12) delivered by the hemagglutinating virus of Japan (HVJ)-liposome (HSP65+IL-12/HVJ). This vaccine provided remarkable protective efficacy in mouse and guinea pig models compared to the BCG vaccine, on the basis of an induction of the CTL activity and improvement of the histopathological tuberculosis lesions, respectively. Furthermore, we extended our studies to a cynomolgus monkey model, which is currently the best animal model of human tuberculosis. This novel vaccine provided a higher level of the protective efficacy than BCG based upon the assessment of mortality, the ESR, body weight, chest X-ray findings and immune responses. Furthermore, the combination of HSP65+IL-12/HVJ and BCG by the priming-booster method showed a synergistic effect in the TB-infected cynomolgus monkey (100% survival). These data indicate that our novel DNA vaccine might be useful against Mycobacterium tuberculosis for human clinical trials.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17280753 DOI： 10.1016/j.vaccine.2007.01.014
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641